{"id":3656255,"date":"2024-10-09T12:58:48","date_gmt":"2024-10-09T16:58:48","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/?post_type=story&p=3656255"},"modified":"2024-11-01T09:44:02","modified_gmt":"2024-11-01T13:44:02","slug":"tl1a-exploring-a-potentially-important-target-for-inflammatory-bowel-disease","status":"publish","type":"story","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/stories\/tl1a-exploring-a-potentially-important-target-for-inflammatory-bowel-disease\/","title":{"rendered":"TL1A: Exploring a potentially important target for inflammatory bowel disease"},"content":{"rendered":"\n
\n
\n \n \n Innovation<\/small>\n <\/a>\n \n \n

\n TL1A: Exploring a potentially important target for inflammatory bowel disease\n <\/h1>\n

Our scientists are investigating ways to modulate TL1A to potentially address inflammation and fibrosis associated with inflammatory bowel disease<\/p>\n <\/div>\n\n

\n

October 9, 2024<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"TL1A\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n

Picture the immune system as a carefully orchestrated network of organs, cells and molecules working together to protect your body from foreign invaders. Normally, this system operates smoothly, identifying and then fighting off microbes. However, in the case of inflammatory bowel disease (IBD), a person\u2019s immune system can mistakenly attack their own tissues, causing chronic inflammation and tissue damage.<\/p>\n\n\n\n

Nearly three million people in the U.S. live with Crohn\u2019s disease or ulcerative colitis, the two most common forms of IBD. Patients with IBD experience symptoms such as diarrhea, blood in the stool, abdominal pain, unintended weight loss, fatigue and impaired sleep. In 25-40% of patients, IBD may affect organs and tissues outside of the gastrointestinal system, including the joints, skin, bones, eyes, kidneys and liver. When IBD is uncontrolled, it can lead to hospitalizations and surgery.<\/p>\n\n\n\n

Despite available therapies which have helped improve patients\u2019 symptoms over the last two decades, many patients do not achieve a state of sustained remission.  <\/p>\n\n\n\n

“People with IBD often struggle to find a treatment that works for them because each individual\u2019s disease is different,” said Aileen Pangan, vice president and therapeutic area head, immunology clinical research, Merck Research Laboratories.<\/p>\n\n\n\n

\n
\n

\u201cWith a better understanding of the biology of IBD, medicines have begun to emerge that aim to change the way we approach treatment. We\u2019re investigating ways to modulate targets, including TL1A, that have been implicated in IBD and other immune-mediated inflammatory diseases.”<\/h4>\n\n\n\n